Winners Circle

[tagthatstock]

IMNR-1.50
The Immune Response Corporation Announces Multiple Sclerosis Phase II Clinical Trial Under New Grant
Tuesday April 6, 7:01 am ET
- Clinical Results Accepted for Presentation at Upcoming AAN Meeting -
CARLSBAD, Calif., April 6 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR - News), a biopharmaceutical company developing immune- based therapies (IBT) for HIV and select other diseases, announced today the awarding of an Immune Tolerance Network grant which will provide the funding for continued research on NeuroVax(TM), an experimental therapy to treat multiple sclerosis (MS). NeuroVax(TM) is a T-cell receptor (TCR) peptide vaccine designed to treat MS through an immunological mechanism of action. Clinical research from a recently completed Phase II study leading to this award has been accepted for presentation at the 54th annual meeting of the American Academy of Neurology (AAN) to be held in late April in San Francisco, CA.

MWY-7.75
CHICAGO, Apr 6, 2004 (BUSINESS WIRE) -- Midway Games Inc. (NYSE:MWY) announced today that it expects its operating results for the three months ended March 31, 2004 to be ahead of the financial guidance provided by the Company on February 25, 2004. For the quarter ended March 31, 2004, Midway expects revenues of approximately $18.0 million, or 50% more than the Company's previously issued revenue guidance of $12.0 million. Midway also projects a net loss for the quarter smaller than the Company's previously issued guidance of $19.0 million but not proportionate to the increase in the revenue guidance for the quarter. Midway attributed the improved financial outlook primarily to strong initial sales of the Company's recently released action-horror game The Suffering. Midway released The Suffering for PlayStation 2 and Xbox on March 8, 2004.